Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat Dose Titration in Pulmonary Hypertension
NCT00454558Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2007
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary arterial hypertension (PAH), sponsored by Bayer. Started Jan 2007; status: completed.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00454558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00454558.